Free Trial

89bio Q4 2024 Earnings Report

89bio logo
$8.47 +0.29 (+3.55%)
As of 03/14/2025 04:00 PM Eastern

89bio EPS Results

Actual EPS
-$1.02
Consensus EPS
-$0.60
Beat/Miss
Missed by -$0.42
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

89bio Earnings Headlines

Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB)
89bio initiated with a Neutral at Goldman Sachs
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
89bio (ETNB) Receives a New Rating from Goldman Sachs
89bio initiated with a Buy at Citi
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat